{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:30:52Z","timestamp":1786995052947,"version":"build-2736575974"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.npep.2026.102585","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:41:35Z","timestamp":1768750895000},"page":"102585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting the brain through the nose: Advances in polymeric nanoparticle delivery for schizophrenia"],"prefix":"10.1016","volume":"116","author":[{"given":"Teja Kumar","family":"Ponduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.N. Koteswara","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0005","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/pharmaceutics15071785","article-title":"Quetiapine albumin nanoparticles as an efficacious platform for brain deposition and potentially improved antipsychotic activity","volume":"15","author":"Abdel-Bar","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0010","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/ph16060886","article-title":"Evaluation of Brain Targeting and Antipsychotic Activity of Nasally Administrated Ziprasidone Lipid\u2013Polymer Hybrid Nanocarriers","volume":"16","author":"Abo El-Enin","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/ph16060886","article-title":"Evaluation of Brain Targeting and Antipsychotic Activity of Nasally Administrated Ziprasidone Lipid\u2013Polymer Hybrid Nanocarriers","volume":"16","author":"Abo El-Enin","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0020","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3390\/app9112219","article-title":"Chitosan-based Nanocarriers for nose to brain delivery","volume":"9","author":"Aderibigbe","year":"2019","journal-title":"Appl. Sci."},{"key":"10.1016\/j.npep.2026.102585_bb0025","first-page":"1","article-title":"Polymer nanoparticles-preparations, applications and future insights: a concise review","volume":"7","author":"Adhikari","year":"2021","journal-title":"Polym.-Plast. Technol. Mater."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/schbul\/sbac113","article-title":"Multimodal magnetic resonance imaging depicts widespread and subregion specific anomalies in the thalamus of early-psychosis and chronic schizophrenia patients","volume":"49","author":"Alem\u00e1n-G\u00f3mez","year":"2023","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.npep.2026.102585_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105564","article-title":"PLGA nanoparticles for nasal drug delivery","volume":"95","author":"Alghareeb","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.npep.2026.102585_bb0040","series-title":"Synthesis and Encapsulation of Antidepressants in Biodegradable Polymeric, Lipid Nanoparticles to Bypass the Blood Brain Barrier","author":"Alkandari","year":"2022"},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0045","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/21691401.2016.1147453","article-title":"The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study","volume":"45","author":"Alzubaidi","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.npep.2026.102585_bb0055","series-title":"Polymeric Nanosystems","first-page":"37","article-title":"Polycaprolactone-based nanoparticles for advanced therapeutic applications","author":"Aminu","year":"2023"},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0060","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00289-021-03598-w","article-title":"S, Ali J. In vitro appraisals and ex vivo permeation prospect of chitosan nanoparticles designed for schizophrenia to intensify nasal delivery","volume":"79","author":"Annu","year":"2022","journal-title":"Polym. Bull."},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0065","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00289-021-03598-w","article-title":"In vitro appraisals and ex vivo permeation prospect of chitosan nanoparticles designed for schizophrenia to intensify nasal delivery","volume":"79","author":"Annu","year":"2022","journal-title":"Polym. Bull."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0070","first-page":"1","article-title":"Formulation and characterization of Asenapine maleate nanoparticles","volume":"40","author":"Appanna Chowdary","year":"2016","journal-title":"International Journal of Pharmaceutical Sciences Review and Research"},{"issue":"18","key":"10.1016\/j.npep.2026.102585_bb0075","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0080","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.apsb.2022.07.003","article-title":"Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders","volume":"13","author":"Awad","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0085","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/pharmaceutics12121230","article-title":"Intranasal Nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders","volume":"12","author":"Bahadur","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0090","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1208\/s12249-014-0189-5","article-title":"Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles","volume":"15","author":"Baltzley","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/17425240902939143","article-title":"The potential for nanoparticle-based drug delivery to the brain: overcoming the blood\u2013brain barrier","volume":"6","author":"Barbu","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0306-4530(85)90056-3","article-title":"Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls","volume":"10","author":"Beckmann","year":"1985","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejpb.2010.12.016","article-title":"Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats","volume":"77","author":"Benvegn\u00fa","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0110","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/pharmaceutics13071088","article-title":"Intranasal Administration for Pain: oxytocin and other polypeptides","volume":"13","author":"Bharadwaj","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.npep.2026.102585_bb0115","first-page":"1629","article-title":"An Overview On Carrier Mediated Nose To Brain Drug Delivery System","volume":"10","author":"Bhosale Ankush","year":"2021","journal-title":"World J Pharm Pharm Sci [Internet]"},{"key":"10.1016\/j.npep.2026.102585_bb0120","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment","volume":"11","author":"Bi","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.npep.2026.102585_bb0125","series-title":"Nasal Drug Delivery in Humans","first-page":"20","author":"Bitter","year":"2011"},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0130","doi-asserted-by":"crossref","DOI":"10.1088\/2053-1591\/3\/12\/125403","article-title":"Factorial design based preparation, optimization, characterization and in vitro drug release studies of olanzapine loaded PLGA nanoparticles","volume":"3","author":"Bohrey","year":"2016","journal-title":"Mater. Res. Express"},{"key":"10.1016\/j.npep.2026.102585_bb0135","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.2147\/IJN.S452316","article-title":"Nose-to-brain drug delivery and Physico-chemical properties of Nanosystems: analysis and correlation studies of data from scientific literature","volume":"19","author":"Bonaccorso","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0140","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/02652040500273753","article-title":"Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol","volume":"22","author":"Budhian","year":"2005","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.npep.2026.102585_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume":"190","author":"Casettari","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0150","first-page":"151","article-title":"Aripiprazole loaded PLGA nanoparticles for controlled release studies: effect of co-polymer ratio","volume":"6","author":"Chandra","year":"2014","journal-title":"Int. J. Drug Deliv."},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0155","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"3\u20134","key":"10.1016\/j.npep.2026.102585_bb0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejps.2006.11.018","article-title":"Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device","volume":"30","author":"Charlton","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.npep.2026.102585_bb0165","first-page":"9","article-title":"Preparation of aripiprazole-poly(methyl vinyl ether- co -maleic anhydride) nanocomposites via supercritical antisolvent process for improved antidepression therapy","volume":"8","author":"Chen","year":"2022","journal-title":"Regen Biomater."},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0170","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/molecules29061390","article-title":"Neurotensin (8\u201313) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets","volume":"29","author":"Cocioab\u0103","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0175","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14116","article-title":"The economic burden of posttraumatic stress disorder in the United States from a societal perspective","volume":"83","author":"Davis","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0180","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/gels8110709","article-title":"Development and evaluation of PLGA nanoparticle-loaded Organogel for the transdermal delivery of risperidone","volume":"8","author":"Dilawar","year":"2022","journal-title":"Gels"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/pharmaceutics12020160","article-title":"Long-acting Paliperidone parenteral formulations based on Polycaprolactone nanoparticles; the influence of stabilizer and chitosan on in vitro release, protein adsorption, and cytotoxicity","volume":"12","author":"Elmowafy","year":"2020","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0190","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3390\/polym15051123","article-title":"Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges","volume":"15","author":"Elmowafy","year":"2023","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.npep.2026.102585_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.npep.2026.102585_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.colsurfb.2011.09.042","article-title":"Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique","volume":"90","author":"Fan","year":"2012","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/pharmaceutics15020678","article-title":"Nanosystems for brain targeting of antipsychotic drugs: an update on the Most promising Nanocarriers for increased bioavailability and therapeutic efficacy","volume":"15","author":"Ferreira","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/pharmaceutics15020678","article-title":"Nanosystems for brain targeting of antipsychotic drugs: an update on the Most promising Nanocarriers for increased bioavailability and therapeutic efficacy","volume":"15","author":"Ferreira","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0215","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.biotechadv.2015.02.010","article-title":"Polymer-based nanoparticles for oral insulin delivery: revisited approaches","volume":"33","author":"Fonte","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.npep.2026.102585_bb0220","article-title":"On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0225","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.npep.2026.102585_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868986","article-title":"Editorial: intranasal drug delivery: challenges and opportunities","volume":"13","author":"Fortuna","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11051-023-05880-6","article-title":"Brain targeting of drugs via intranasal route in conjunction with nanoparticle-based systems: an updated review","volume":"25","author":"Furquan","year":"2023","journal-title":"J. Nanopart. Res."},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0240","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s13346-022-01245-z","article-title":"Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins","volume":"13","author":"Gabold","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0255","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5530\/ijper.56.1.8","article-title":"Effect of formulation variables on fabrication of risperidone loaded nanoparticles for sustained drug delivery","volume":"56","author":"Gohil","year":"2022","journal-title":"Indian Journal of Pharmaceutical Education and Research."},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0265","doi-asserted-by":"crossref","first-page":"23909","DOI":"10.3390\/ijms151223909","article-title":"PLGA biodegradable nanoparticles containing Perphenazine or chlorpromazine hydrochloride: effect of formulation and release","volume":"15","author":"Halayqa","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.carbpol.2012.02.051","article-title":"Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation","volume":"89","author":"Haque","year":"2012","journal-title":"Carbohydr. Polym."},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0275","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1208\/s12249-016-0657-1","article-title":"Paliperidone-loaded Nanolipomer system for sustained delivery and enhanced intestinal permeation: superiority to polymeric and solid lipid nanoparticles","volume":"18","author":"Helal","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0280","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejpb.2008.10.009","article-title":"Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue","volume":"72","author":"Horv\u00e1t","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41386-022-01426-x","article-title":"Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes","volume":"48","author":"Howes","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102585_bb0290","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","article-title":"Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson\u2019s disease","volume":"415","author":"Hu","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"1\u20133","key":"10.1016\/j.npep.2026.102585_bb0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery \u2014 recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.npep.2026.102585_bb0305","series-title":"FDA\/Center for Drug Evaluation and Research","author":"Inactive Ingredient Search for Approved Drug Products","year":"2024"},{"key":"10.1016\/j.npep.2026.102585_bb0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jmmm.2018.08.048","article-title":"Magnetic drilling enhances intra-nasal transport of particles into rodent brain","volume":"469","author":"Jafari","year":"2019","journal-title":"J. Magn. Magn. Mater."},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0315","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/molecules28041963","article-title":"Chitosan-based nanoparticles as effective drug delivery systems\u2014a review","volume":"28","author":"Jafernik","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Investig."},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0325","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/pharmaceutics16121611","article-title":"Drug Delivery Across the Blood\u2013Brain Barrier: A New Strategy for the Treatment of Neurological Diseases","volume":"16","author":"Jiao","year":"2024","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121611","article-title":"Drug delivery across the blood-brain barrier: a new strategy for the treatment of neurological diseases","volume":"16","author":"Jiao","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.npep.2026.102585_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.npep.2026.102585_bb0340","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejps.2017.03.050","article-title":"Design and in vivo evaluation of solid lipid nanoparticulate systems of olanzapine for acute phase schizophrenia treatment: investigations on antipsychotic potential and adverse effects","volume":"104","author":"Joseph","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102585_bb0345","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2018.02.010","article-title":"DoE based olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model","volume":"541","author":"Joseph","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0350","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1573413718666220929102013","article-title":"Polymeric nanoparticles: prospective on the synthesis, characterization and applications in nose-to-brain drug delivery","volume":"19","author":"Kendre","year":"2023","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.npep.2026.102585_bb0355","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","article-title":"Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?","volume":"71","author":"Kreuter","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0360","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"issue":"si4","key":"10.1016\/j.npep.2026.102585_bb0365","article-title":"Design, optimization and evaluation of intranasal Nanotherapeutic of atypical antipsychotic drug","volume":"12","author":"Kumar","year":"2023","journal-title":"europeanchemicalbulletin"},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0370","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000110430","article-title":"Molecular mechanisms of schizophrenia","volume":"20","author":"Lang","year":"2007","journal-title":"Cell. Physiol. Biochem."},{"issue":"15","key":"10.1016\/j.npep.2026.102585_bb0375","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","article-title":"Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0380","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/pharmaceutics15051554","article-title":"Development of lyophilised Eudragit\u00ae retard nanoparticles for the sustained release of clozapine via intranasal administration","volume":"15","author":"Lombardo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12951-020-00709-z","article-title":"Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity","volume":"18","author":"Lugasi","year":"2020","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0390","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/polym13071000","article-title":"Development of a new polymeric Nanocarrier dedicated to controlled clozapine delivery at the dopamine D2-serotonin 5-HT1A Heteromers","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.npep.2026.102585_bb0395","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.colsurfb.2015.12.044","article-title":"Encapsulation of clozapine in polymeric nanocapsules and its biological effects","volume":"140","author":"\u0141ukasiewicz","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.npep.2026.102585_bb0400","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.colsurfb.2017.07.053","article-title":"The interaction of clozapine loaded nanocapsules with the hCMEC\/D3 cells \u2013 in vitro model of blood brain barrier","volume":"159","author":"\u0141ukasiewicz","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0405","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11051-019-4587-1","article-title":"Encapsulation of clozapine into polycaprolactone nanoparticles as a promising strategy of the novel nanoformulation of the active compound","volume":"21","author":"\u0141ukasiewicz","year":"2019","journal-title":"J. Nanopart. Res."},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0410","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.xphs.2015.12.016","article-title":"Development and evaluation of a novel intranasal spray for the delivery of amantadine","volume":"105","author":"Lungare","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.npep.2026.102585_bb0415","article-title":"Neurobiology of schizophrenia: a comprehensive review","volume":"14","author":"Luvsannyam","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0425","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/adt.2023.089","article-title":"Optimization of Lurasidone HCl-loaded PLGA nanoparticles for intramuscular delivery: enhanced bioavailability, reduced dosing frequency, pharmacokinetics, and therapeutic outcomes","volume":"22","author":"Macwan","year":"2024","journal-title":"Assay Drug Dev. Technol."},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0430","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/pharmaceutics15030746","article-title":"Intranasal polymeric and lipid-based Nanocarriers for CNS drug delivery","volume":"15","author":"Maher","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.npep.2026.102585_bb0435","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jconrel.2020.12.050","article-title":"In situ-gelling starch nanoparticle (SNP)\/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide","volume":"330","author":"Majcher","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010028","article-title":"Long-acting injectable antipsychotics-a review on formulation and in vitro dissolution","volume":"16","author":"Markowicz-Piasecka","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.npep.2026.102585_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102374","article-title":"Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 omicron infection in healthcare workers: a prospective cohort study","volume":"67","author":"Mi","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0455","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/colloids7010023","article-title":"Nose-to-brain targeting via Nanoemulsion: significance and evidence","volume":"7","author":"Misra","year":"2023","journal-title":"Colloids Interfaces"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0460","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0465","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0470","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/15622975.2012.677547","article-title":"Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case\u2013control study","volume":"14","author":"Montag","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0475","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/17435889.3.3.305","article-title":"Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation","volume":"3","author":"Muthu","year":"2008","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0480","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nano.2008.12.003","article-title":"PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation","volume":"5","author":"Muthu","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.npep.2026.102585_bb0485","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.brainresbull.2018.08.003","article-title":"Ligand conjugation: an emerging platform for enhanced brain drug delivery","volume":"142","author":"Nabi","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.npep.2026.102585_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120807","article-title":"PLGA-based nanomedicines manufacturing: technologies overview and challenges in industrial scale-up","volume":"605","author":"Operti","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0495","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10837450.2014.965324","article-title":"Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles","volume":"21","author":"Panda","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.npep.2026.102585_bb0500","first-page":"13","article-title":"Advances and challenges in intranasal delivery of antipsychotic agents targeting the central nervous system","volume":"24","author":"Pandey","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRX"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0510","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRX"},{"issue":"9","key":"10.1016\/j.npep.2026.102585_bb0515","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/00914037.2022.2052728","article-title":"Development of thiolated polyethylene glycol-poly (lactic-co-glycolic acid) co-polymeric nanoparticles for intranasal delivery of quetiapine: in vitro \u2013 ex vivo characterization","volume":"72","author":"Patil","year":"2023","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2014.02.007","article-title":"Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)\u2013block-poly(d,l)-lactic-co-glycolic acid (PEG\u2013PLGA) nanoparticles for the treatment of schizophrenia","volume":"87","author":"Piazza","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0525","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2014.02.007","article-title":"Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)\u2013block-poly(d,l)-lactic-co-glycolic acid (PEG\u2013PLGA) nanoparticles for the treatment of schizophrenia","volume":"87","author":"Piazza","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.npep.2026.102585_bb0530","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0535","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1021\/acs.molpharmaceut.5c00863","article-title":"Transferrin-conjugated chitosan nanoparticles for direct nose-to-brain delivery of ziprasidone: pharmacokinetic and Pharmacodynamic evaluation","volume":"22","author":"Ponduri","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.npep.2026.102585_bb0540","article-title":"Mucoadhesive and mucus-penetrating interpolyelectrolyte complexes for nose-to-brain drug delivery","volume":"37","author":"Porfiryeva","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.npep.2026.102585_bb0545","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2016.12.003","article-title":"Influence of different stabilizers on the encapsulation of desmopressin acetate into PLGA nanoparticles","volume":"118","author":"Primavessy","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0550","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/nano12030576","article-title":"Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles","volume":"12","author":"Pulingam","year":"2022","journal-title":"Nanomaterials"},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0555","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1567201815666181011121750","article-title":"Formulation and evaluation of neuroactive drug loaded chitosan nanoparticle for nose to brain delivery: in-vitro characterization and in-vivo behavior study","volume":"16","author":"Qureshi","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.npep.2026.102585_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104756","article-title":"Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders","volume":"86","author":"Raghav","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.npep.2026.102585_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104726","article-title":"Recent advances in nanotechnology for intra-nasal drug delivery and clinical applications","volume":"86","author":"Rai","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.npep.2026.102585_bb0570","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2147\/IJN.S42783","article-title":"Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model","author":"Re","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.npep.2026.102585_bb0575","series-title":"Handbook of Pharmaceutical Excipients","author":"Rowe","year":"2009"},{"issue":"1\u20133","key":"10.1016\/j.npep.2026.102585_bb0580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2010.09.014","article-title":"Peripheral oxytocin is associated with reduced symptom severity in schizophrenia","volume":"124","author":"Rubin","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.npep.2026.102585_bb0585","doi-asserted-by":"crossref","first-page":"034","DOI":"10.7324\/JAPS.2016.60905","article-title":"Formulation and evaluation of olanzapine loaded chitosan nanoparticles for nose to brain targeting an in vitro and ex vivo toxicity study","author":"Ruby","year":"2016","journal-title":"J Appl Pharm Sci."},{"issue":"8","key":"10.1016\/j.npep.2026.102585_bb0590","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/03639045.2019.1619759","article-title":"Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery","volume":"45","author":"Rukmangathen","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8","key":"10.1016\/j.npep.2026.102585_bb0595","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/03639045.2019.1619759","article-title":"Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery","volume":"45","author":"Rukmangathen","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0600","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nano.2006.11.008","article-title":"The present and future of nanotechnology in human health care","volume":"3","author":"Sahoo","year":"2007","journal-title":"Nanomedicine"},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102585_bb0605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF03402101","article-title":"Schizophrenia: neural mechanisms for novel therapies","volume":"9","author":"Sawa","year":"2003","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0610","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","article-title":"Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies","volume":"7","author":"Seju","year":"2011","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0615","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43094-020-00156-5","article-title":"Comparative evaluation of intranasally delivered quetiapine loaded mucoadhesive microemulsion and polymeric nanoparticles for brain targeting: pharmacokinetic and gamma scintigraphy studies","volume":"7","author":"Shah","year":"2021","journal-title":"Futur J Pharm Sci."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0620","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43094-020-00156-5","article-title":"Comparative evaluation of intranasally delivered quetiapine loaded mucoadhesive microemulsion and polymeric nanoparticles for brain targeting: pharmacokinetic and gamma scintigraphy studies","volume":"7","author":"Shah","year":"2021","journal-title":"Futur J Pharm Sci."},{"issue":"7","key":"10.1016\/j.npep.2026.102585_bb0625","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/ajp.154.7.1019","article-title":"CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder","volume":"154","author":"Sharma","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0630","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/polym8030083","article-title":"Decorating nanoparticle surface for targeted drug delivery: opportunities and challenges","volume":"8","author":"Shen","year":"2016","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.npep.2026.102585_bb0635","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12668-023-01290-z","article-title":"Fabrication of PF-127 based Niosomal in situ gel for intranasal delivery of Lurasidone hydrochloride and optimization by using 32 factorial design","volume":"14","author":"Shikalgar","year":"2024","journal-title":"Bionanoscience"},{"key":"10.1016\/j.npep.2026.102585_bb0640","first-page":"1","article-title":"Recent prospective of surface engineered nanoparticles in the management of neurodegenerative disorders","volume":"24","author":"Singh","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0645","doi-asserted-by":"crossref","first-page":"54","DOI":"10.36922\/an.5140","article-title":"Targeted protein degraders: blood\u2013brain barrier permeability and central nervous system exposure","volume":"4","author":"Singh","year":"2025","journal-title":"Adv. Neurol."},{"issue":"2","key":"10.1016\/j.npep.2026.102585_bb0650","doi-asserted-by":"crossref","first-page":"54","DOI":"10.36922\/an.5140","article-title":"Targeted protein degraders: blood\u2013brain barrier permeability and central nervous system exposure","volume":"4","author":"Singh","year":"2025","journal-title":"Adv. Neurol."},{"issue":"8","key":"10.1016\/j.npep.2026.102585_bb0655","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41380-019-0601-3","article-title":"Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings","volume":"25","author":"Smigielski","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.npep.2026.102585_bb0660","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0665","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified Nanocarriers for nose-to-brain delivery: from bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.npep.2026.102585_bb0670","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/17425247.2023.2263363","article-title":"Nasal delivery as a strategy for the prevention and treatment of COVID-19","volume":"20","author":"Sonvico","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0675","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1192\/bjp.188.6.510","article-title":"Brain volume in first-episode schizophrenia","volume":"188","author":"Steen","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.npep.2026.102585_bb0680","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0685","first-page":"29","article-title":"Formulation and evaluation of capsules of asenapine maleate loaded chitosan nanoparticles","volume":"2","author":"Supriya","year":"2018","journal-title":"Acta Sci. Pharmaceu. Sci."},{"issue":"6","key":"10.1016\/j.npep.2026.102585_bb0690","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17425247.2020.1762563","article-title":"Nose-to-brain delivery of antipsychotics using nanotechnology: a review","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0695","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.npep.2026.102585_bb0700","doi-asserted-by":"crossref","unstructured":"Tewari AK, Upadhyay SC, Kumar M, Pathak K, Kaushik D, Verma R, Bhatt S, Massoud EES, Rahman M.D.H, Cavalu S. Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic. Polymers (Basel). 2022 Aug29;14(17):3545.","DOI":"10.3390\/polym14173545"},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0705","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1017\/S003329172200174X","article-title":"Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18 FDG-PET studies in schizophrenia","volume":"53","author":"Townsend","year":"2023","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0710","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9690","key":"10.1016\/j.npep.2026.102585_bb0715","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0720","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MS21078COM5","article-title":"The epidemiology and global burden of schizophrenia","volume":"84","author":"Velligan","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.npep.2026.102585_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.reactfunctpolym.2020.104493","article-title":"Chitosan-coated nanocapsules ameliorates the effect of olanzapine in prepulse inhibition of startle response (PPI) in rats following oral administration","volume":"148","author":"Veragten","year":"2020","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.npep.2026.102585_bb0730","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.colsurfb.2016.05.065","article-title":"A surface modification of clozapine-loaded nanocapsules improves their efficacy: a study of formulation development and biological assessment","volume":"145","author":"Vieira","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.npep.2026.102585_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104421","article-title":"Intranasal transmucosal drug delivery: an alternative approach to the parenteral route for medical emergencies","volume":"83","author":"Vitore","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"3","key":"10.1016\/j.npep.2026.102585_bb0740","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0928-0987(98)00023-2","article-title":"Nasal drug delivery \u2013 evaluation of an in vitro model using porcine nasal mucosa","volume":"7","author":"Wadell","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0745","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.npep.2026.102585_bb0750","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.npep.2026.102585_bb0755","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJN.S151475","article-title":"Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects","volume":"13","author":"Yan","year":"2018","journal-title":"Int. J. Nanomedicine"},{"issue":"11","key":"10.1016\/j.npep.2026.102585_bb0760","doi-asserted-by":"crossref","first-page":"94907836","DOI":"10.26599\/NR.2025.94907836","article-title":"Functional nanomaterial strategies for targeted CNS drug delivery","volume":"18","author":"Ye","year":"2025","journal-title":"Nano Res."},{"key":"10.1016\/j.npep.2026.102585_bb0765","first-page":"1","article-title":"Design of Nanoparticle-Based Carriers for targeted drug delivery","volume":"2016","author":"Yu","year":"2016","journal-title":"J. Nanomater."},{"key":"10.1016\/j.npep.2026.102585_bb0770","first-page":"13","article-title":"Drug-loaded PEG-PLGA nanoparticles for cancer treatment","volume":"19","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.npep.2026.102585_bb0775","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/s41380-024-02426-7","article-title":"Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk","volume":"29","author":"Zhu","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"22","key":"10.1016\/j.npep.2026.102585_bb0780","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/molecules25225294","article-title":"Nano carrier drug delivery Systems for the Treatment of neuropsychiatric disorders: advantages and limitations","volume":"25","author":"Zorkina","year":"2020","journal-title":"Molecules"}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:47:29Z","timestamp":1772588849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417926000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":155,"alternative-id":["S0143417926000016"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2026.102585","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the brain through the nose: Advances in polymeric nanoparticle delivery for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2026.102585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102585"}}